Kobo Biotech

Hyderabad, India Founded: 1993 • Age: 33 yrs Listed

Produces high-quality active pharmaceutical ingredients and specialty chemicals for cosmetics and pharmaceutical industries.

Request Access

Page last updated 19 Oct 2026

About Kobo Biotech

Kobo Biotech is a publicly listed company based in Hyderabad (India) founded in 1993. It produces high-quality active pharmaceutical ingredients and specialty chemicals for cosmetics and pharmaceutical industries. It operates on a B2B model. The company has 1 employees. Its Indian entity Kobo Biotech Limited reported revenue of ₹1.5 Lakh. Its focus areas include Biotechnology, Pharmaceutical Manufacturing and Specialty Chemicals. Similar companies include Laurus Labs, Symbiotec and SeQuent; 2 of its 3 listed similar companies have raised funding.

Company details

Kobo Biotech produces high-quality active pharmaceutical ingredients and specialty chemicals for cosmetics and pharmaceutical industries through providing healthcare solutions, advancing biotech innovations, pharmaceutical manufacturing, and specialty chemicals. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field.

Headquarters Hyderabad, India
Employees 1
Stage Public
Sectors
Healthcare
Website kobobiotech.com
Legal Name Kobo Biotech Ltd

Operational Areas

Healthcare → Pharmaceuticals & Distribution

Key Metrics

Market Cap
₹9.22 Cr
KOBO · BSE
Share Price
₹3.80
-1.81% today
Revenue
₹103 Cr
FY 2014-15 · 0.0% YoY
EBITDA
−₹0.91 Cr
Margin -0.9%
Net Profit
−₹34.80 Cr
FY 2014-15 · 0.0% YoY
Debt / Equity
3.38
Interest cover -227.7x
Employee Count
1

Associated legal entities of Kobo Biotech

Kobo Biotech operates through Kobo Biotech Limited, a listed company (under cirp). Its filings, financials, charges and directors are on the company page.

Legal entity	Status	Incorporated	Registered in	Revenue (FY 2023)	Employees	Directors	Company page
Kobo Biotech Limited Listed CIN L24110TG1993PLC016112	Under Cirp	03 Aug 1993	Hyderabad, Telangana	₹0.0 Cr	1	5	View details

Board of directors of Kobo Biotech Limited (Kobo Biotech)

Kobo Biotech Limited is the primary company behind Kobo Biotech. The board of Kobo Biotech Limited currently have 4 directors; the longest-serving is Ajit Annu Kamath, appointed in 2009. 24 earlier directors have ceased.

Director	Designation	Appointed	Tenure	Entity
Ajit Annu Kamath DIN 00032799	Director	31 Jan 2009	17 yrs 8 mo	Kobo Biotech Limited
Rajendrakumar Padmanabhan Kaimal DIN 00032839	Director	30 May 2013	13 yrs 5 mo	Kobo Biotech Limited
Sunil Mansukhlal Pitroda DIN 07028212	Director	31 Mar 2018	8 yrs 7 mo	Kobo Biotech Limited
Urja Vijaykumar Shah DIN 06672899	Director	27 Dec 2018	7 yrs 10 mo	Kobo Biotech Limited

IPO & Listings of Kobo Biotech

Kobo Biotech is a publicly listed company on the BSE with ticker symbol KOBO in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Listed onBSE: KOBO
Listed entityKobo Biotech Ltd
Exchange sectorHealth technology
ISININE881A01015
Share price₹4.52 (-1.95% on the day) · 2026-10-14
Market capitalisation₹11.0 Cr
Volume (last session)6,316

Financials of Kobo Biotech

Exchange-reported figures of Kobo Biotech Limited, the listed company behind Kobo Biotech (BSE: KOBO).

Financial Highlights

FY 2014-15 · Consolidated

Revenue

₹103 Cr

0.0% YoY

EBITDA

−₹0.91 Cr

0.0% YoY

Profit After Tax

−₹34.80 Cr

0.0% YoY

Net Worth

₹53.08 Cr

0.0% YoY

Total Assets

₹264 Cr

0.0% YoY

Total Debt

₹179 Cr

0.0% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

Metrics	FY 2014-15	FY 2013-14	FY 2012-13
Income statement
Revenue	103	103	404
Revenue growth	0.0%	-74.4%	-
EBITDA	(0.91)	(0.91)	42.87
EBITDA margin	-0.9%	-0.9%	+10.6%
Profit before tax	(34.26)	(34.26)	14.86
Net profit	(34.80)	(34.80)	13.98
Net profit margin	-33.7%	-33.7%	+3.5%
EPS (₹)	(15.47)	0.00	6.22
Balance sheet
Total assets	264	264	302
Net worth	53.08	53.08	87.89
Total debt	179	179	182
Cash & bank	5.64	5.64	16.48
Net working capital	161	161	193
Cash flow
Cash from operations	6.72	6.72	36.72
Cash from investing	(4.71)	(4.71)	(6.99)
Cash from financing	(12.85)	(12.85)	(38.39)

Metrics	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20	FY 2018-19
Income statement
Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	(1.23)	(0.88)	(1.50)	(10.50)	(2.78)	(0.69)	(3.90)
Profit before tax	(5.22)	(4.93)	(5.55)	(15.22)	(19.22)	(21.01)	(24.46)
Net profit	(5.22)	(4.93)	(5.55)	(15.22)	(19.22)	(21.01)	(22.28)
EPS (₹)	(2.20)	(2.07)	(2.33)	(6.39)	(8.07)	(8.82)	(10.27)
Balance sheet
Total assets	3.33	8.56	13.64	20.06	155	165	172
Net worth	(138)	(133)	(128)	(122)	(107)	(87.97)	(66.96)
Total debt	140	140	140	141	261	251	236
Cash & bank	4.36	0.18	0.13	0.13	1.56	0.13	0.13
Net working capital	(23.13)	(21.97)	(20.96)	(18.60)	87.07	90.91	91.64
Cash flow
Cash from operations	4.18	0.20	0.87	93.76	2.51	14.48	20.95
Cash from investing	0.00	0.00	0.00	25.09	0.00	0.00	0.00
Cash from financing	0.00	(0.15)	(0.87)	(120)	(1.08)	(14.47)	(20.95)

Particulars	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other income	0.02	0.00	0.00	0.00	0.02	0.00	0.00	0.00
Total expenses	0.34	0.25	0.20	0.20	0.23	0.79	0.17	0.21
EBITDA	(0.34)	(0.25)	(0.20)	(0.20)	(0.23)	(0.79)	(0.17)	(0.21)
Depreciation	1.01	1.01	1.03	1.02	1.01	1.00	1.03	0.89
Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Profit before tax	(1.33)	(1.26)	(1.23)	(1.22)	(1.22)	(1.79)	(1.20)	(1.10)
Tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 30 Oct 2026

Particulars	FY 2014-15	FY 2013-14	FY 2012-13
Revenue	103	103	404
Revenue growth	0.0%	-74.4%	-
Other income	0.25	0.25	0.37
Total expenses	104	104	361
Employee cost	9.03	9.03	12.25
EBITDA	(0.91)	(0.91)	42.87
EBITDA margin	-0.9%	-0.9%	+10.6%
Depreciation	9.62	9.62	9.97
Interest	23.98	23.98	18.41
Profit before tax	(34.26)	(34.26)	14.86
Tax	0.54	0.54	1.21
Net profit	(34.80)	(34.80)	13.98
Net profit margin	-33.7%	-33.7%	+3.5%
EPS (₹)	(15.47)	0.00	6.22

Particulars	FY 2014-15	FY 2013-14	FY 2012-13
Equity & liabilities
Share capital	22.50	22.50	22.50
Reserves & surplus	30.58	30.58	65.39
Shareholders' funds (net worth)	53.08	53.08	87.89
Minority interest	0.00	0.00	0.00
Secured loans	163	163	143
Unsecured loans	16.05	16.05	38.68
Total debt	179	179	182
Total liabilities	264	264	302
Assets
Gross block	192	192	187
Net block	104	104	108
Capital work in progress	2.25	2.25	2.92
Investments	0.00	0.00	0.00
Inventories	76.01	76.01	59.31
Sundry debtors	190	190	205
Cash & bank balances	5.64	5.64	16.48
Loans & advances	18.53	18.53	20.47
Total current assets	290	290	301
Total current liabilities	129	129	108
Net working capital	161	161	193
Total assets	264	264	302

Particulars	FY 2014-15	FY 2013-14	FY 2012-13
Opening cash	16.48	16.48	25.14
Net cash from operating activities	6.72	6.72	36.72
Net cash from investing activities	(4.71)	(4.71)	(6.99)
Net cash from financing activities	(12.85)	(12.85)	(38.39)
Net change in cash	(10.84)	(10.84)	(8.66)
Closing cash	5.64	5.64	16.48

Particulars	FY 2014-15	FY 2013-14	FY 2012-13
Growth
Sales growth	0.0%	-74.4%	-
EBITDA growth	0.0%	-102.1%	-
PBT growth	0.0%	-	+9997.0%
Net income growth	0.0%	-348.9%	-
Profitability & leverage
Net income margin	-33.7%	-33.7%	+3.4%
Return on capital employed	0.0%	0.0%	+12.6%
Return on net worth	0.0%	0.0%	+16.7%
Debt / equity	3.38	2.56	1.83
Long-term debt / equity	0.70	0.55	0.52
Interest cover	-227.73	-227.73	55.96
Efficiency & per share
Fixed asset turnover	0.54	0.55	2.32
Inventory turnover	1.37	1.54	7.98
Debtors turnover	0.55	0.53	2.35
EPS (₹)	(15.47)	0.00	6.22
Dividend per share (₹)	0.00	0.00	0.00
Book value per share (₹)	23.59	23.59	39.06

Particulars	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other income	0.02	0.00	0.00	0.00	0.02	0.00	0.00	0.00
Total expenses	0.34	0.25	0.20	0.20	0.23	0.79	0.17	0.21
EBITDA	(0.34)	(0.25)	(0.20)	(0.20)	(0.23)	(0.79)	(0.17)	(0.21)
Depreciation	1.01	1.01	1.03	1.02	1.01	1.00	1.03	0.89
Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Profit before tax	(1.33)	(1.26)	(1.23)	(1.22)	(1.22)	(1.79)	(1.20)	(1.10)
Tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

Particulars	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20	FY 2018-19
Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other income	0.08	0.02	0.02	0.02	0.04	0.03	0.03
Total expenses	1.23	0.88	1.50	10.50	2.78	0.69	3.90
Employee cost	0.19	0.25	0.23	0.72	1.39	1.80	2.08
EBITDA	(1.23)	(0.88)	(1.50)	(10.50)	(2.78)	(0.69)	(3.90)
Depreciation	4.07	4.07	4.07	4.61	5.64	5.88	6.15
Interest	0.00	0.00	0.00	0.13	10.84	14.47	14.44
Profit before tax	(5.22)	(4.93)	(5.55)	(15.22)	(19.22)	(21.01)	(24.46)
Tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net profit	(5.22)	(4.93)	(5.55)	(15.22)	(19.22)	(21.01)	(22.28)
EPS (₹)	(2.20)	(2.07)	(2.33)	(6.39)	(8.07)	(8.82)	(10.27)

Particulars	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20	FY 2018-19
Equity & liabilities
Share capital	23.83	23.83	23.83	23.83	23.83	23.83	23.83
Reserves & surplus	(162)	(157)	(152)	(146)	(131)	(112)	(90.79)
Shareholders' funds (net worth)	(138)	(133)	(128)	(122)	(107)	(87.97)	(66.96)
Secured loans	108	108	108	109	229	219	205
Unsecured loans	31.71	31.71	31.71	31.71	31.71	31.71	31.71
Total debt	140	140	140	141	261	251	236
Total liabilities	3.33	8.56	13.64	20.06	155	165	172
Assets
Gross block	104	104	104	104	192	192	192
Net block	29.45	33.52	37.59	41.66	56.91	62.54	68.42
Capital work in progress	0.00	0.00	0.00	0.00	2.25	2.25	2.25
Investments	0.00	0.00	0.00	0.00	12.19	12.19	12.19
Inventories	18.04	18.04	18.04	18.04	53.28	53.28	53.28
Sundry debtors	12.01	11.97	11.95	11.80	92.47	93.29	90.61
Cash & bank balances	4.36	0.18	0.13	0.13	1.56	0.13	0.13
Loans & advances	7.73	7.69	7.62	7.56	11.92	12.65	12.56
Total current assets	42.14	37.88	37.74	37.53	159	159	157
Total current liabilities	65.27	59.85	58.70	56.13	72.16	68.44	64.94
Net working capital	(23.13)	(21.97)	(20.96)	(18.60)	87.07	90.91	91.64
Total assets	3.33	8.56	13.64	20.06	155	165	172

Particulars	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20	FY 2018-19
Opening cash	0.18	0.13	0.13	1.56	0.13	0.13	0.13
Net cash from operating activities	4.18	0.20	0.87	93.76	2.51	14.48	20.95
Net cash from investing activities	0.00	0.00	0.00	25.09	0.00	0.00	0.00
Net cash from financing activities	0.00	(0.15)	(0.87)	(120)	(1.08)	(14.47)	(20.95)
Net change in cash	4.18	0.05	0.00	(1.43)	1.43	0.00	0.00
Closing cash	4.36	0.18	0.13	0.13	1.56	0.13	0.13

Particulars	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20	FY 2018-19
Growth
EBITDA growth	-39.8%	+41.3%	+85.7%	-277.7%	-302.9%	+82.3%	-
PBT growth	-5.9%	+11.2%	+63.5%	+20.8%	+8.5%	+14.1%	-2.3%
Net income growth	-5.9%	+11.2%	+63.5%	+20.8%	+8.5%	+5.7%	-
Revenue CAGR (3Y)	-	-	-	-	-	-	-100.0%
EBITDA CAGR (3Y)	-51.1%	-31.9%	+29.5%	+39.1%	-2.7%	-44.5%	-
Profitability & leverage
Return on capital employed	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Return on net worth	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Debt / equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-term debt / equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest cover	0.00	0.00	0.00	-0.86	-128.74	-220.24	-143.68
Efficiency & per share
Fixed asset turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debtors turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EPS (₹)	(2.20)	(2.07)	(2.33)	(6.39)	(8.07)	(8.82)	(10.27)
Dividend per share (₹)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Book value per share (₹)	(57.98)	(55.79)	(53.72)	(51.39)	(45.00)	(36.92)	(28.11)

Similar companies to Kobo Biotech

Kobo Biotech has 3 listed similar companies in our database, 2 of them funded. They include Laurus Labs, Symbiotec and SeQuent.

Company Name	Domain	Founded	HQ Location	Total funding	Employees	Description
Laurus Labs	lauruslabs.com	2005	Hyderabad, India	$229.73M	6,035	Pharmaceutical and biotechnology company
Symbiotec	symbiotec.in	2002	Indore, India	$61.01M	1,822	Non-sterile steroid hormone-based APIs and intermediates are manufactured.
SeQuent	sequent.in	2002	Bengaluru, India			APIs are developed and manufactured for therapeutic areas.

Premium access

Detailed similar companies of Kobo Biotech

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

Full competitor set
Operating metrics
Benchmarks
Competitive positioning

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.

Included in your Premium account

✓
Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
✓
Full access to every database India & global coverage, advanced filters and rich profile details
✓
Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Kobo Biotech

When was Kobo Biotech founded?

Kobo Biotech was founded in 1993.

Where is Kobo Biotech located?

Kobo Biotech is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.

How many employees does Kobo Biotech have?

Kobo Biotech has 1 employees.

What is the annual revenue of Kobo Biotech?

The primary company behind Kobo Biotech, Kobo Biotech Limited, reported revenue of ₹1.5 Lakh for FY 2023, down 8% year on year.

What does Kobo Biotech do?

Which companies are similar to Kobo Biotech?

Kobo Biotech's top competitors include Laurus Labs, Symbiotec and SeQuent.

Is Kobo Biotech publicly traded?

Yes, Kobo Biotech is publicly traded on BSE under the ticker symbol KOBO.

Which legal entities are associated with Kobo Biotech?

Kobo Biotech operates through Kobo Biotech Limited.

Who are the directors of Kobo Biotech?

The legal entities of Kobo Biotech currently have 5 directors, including Sunil Mansukhlal Pitroda, Ajit Annu Kamath, Urja Vijaykumar Shah and others.

Kobo Biotech